E-LIB Suche - Ergebnisse für: Cloughesy, T.

1

P11.29.B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE ..:

Weller, M ; Alexander, B ; Berry, D...
Neuro-Oncology. 25 (2023) Supplement_2 - p. ii79-ii80 , 2023

Link: https://doi.org/10.1093/..

2

OS09.4.A RANO 2.0: UPDATE TO THE RESPONSE ASSESSMENT IN NEU..:

Wen, P ; Van Den Bent, M ; Youssef, G...
Neuro-Oncology. 25 (2023) Supplement_2 - p. ii21-ii21 , 2023

Link: https://doi.org/10.1093/..

3

The CNS-penetrant EGFR inhibitor, ERAS-801, shows promising..:

Tsang, J. ; Zhao, E. ; Plawat, R...
European Journal of Cancer. 174 (2022) - p. S32 , 2022

Link: https://doi.org/10.1016/..

4

P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform t..:

Weller, M ; Ellingson, B ; Alexander, B...
Neuro-Oncology. 24 (2022) Supplement_2 - p. ii73-ii73 , 2022

Link: https://doi.org/10.1093/..

5

P05.06 Phase 2 study to evaluate the safety, pharmacokineti..:

Wen, P Y ; de Groot, J ; Battiste, J D...
Neuro-Oncology. 21 (2019) Supplement_3 - p. iii35-iii35 , 2019

Link: https://doi.org/10.1093/..

6

OS10.6 Infigratinib (BGJ398) in patients with recurrent gli..:

Lassman, A B ; Sepúlveda-Sánchez, J M ; Cloughesy, T...
Neuro-Oncology. 21 (2019) Supplement_3 - p. iii21-iii22 , 2019

Link: https://doi.org/10.1093/..

7

P01.032Associations of anticoagulant use with outcome in ne..:

Le Rhun, E ; Genbrugge, E ; Stupp, R...
Neuro-Oncology. 20 (2018) suppl_3 - p. iii235-iii235 , 2018

Link: https://doi.org/10.1093/..

8

OS07.3 Nivolumab in Combination With Radiotherapy With or W..:

Omuro, A. ; Vlahovic, G. ; Baehring, J....
Neuro-Oncology. 19 (2017) suppl_3 - p. iii13-iii13 , 2017

Link: https://doi.org/10.1093/..

9

26LBA Does valproic acid improve survival in glioblastoma? ..:

Happold, C. ; Gorlia, T. ; Chinot, O....
European Journal of Cancer. 51 (2015) - p. S723 , 2015

Link: https://doi.org/10.1016/..

10

ET-12 * PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERS..:

Cloughesy, T. ; Finocchiaro, G. ; Belda-Iniesta, C....
Neuro-Oncology. 16 (2014) suppl 5 - p. v81-v81 , 2014

Link: https://doi.org/10.1093/..

11

NI-55 * PARAMETRIC MAPS OF CONTRAST AGENT DIFFUSION USING A..:

Leu, K. ; Tran, A. ; Pope, W....
Neuro-Oncology. 16 (2014) suppl 5 - p. v150-v150 , 2014

Link: https://doi.org/10.1093/..

12

AT-18 * SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO ..:

Cloughesy, T. ; Wick, W. ; Mason, W....
Neuro-Oncology. 16 (2014) suppl 5 - p. v12-v12 , 2014

Link: https://doi.org/10.1093/..

13

BI-22 * CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURV..:

Phillips, H. ; Sandmann, T. ; Li, C....
Neuro-Oncology. 16 (2014) suppl 5 - p. v28-v28 , 2014

Link: https://doi.org/10.1093/..

14

NI-68 * 18F-FDOPA PET IN TREATED LOW-GRADE GLIOMAS WITH NON..:

Schwarzenberg, J. ; Czernin, J. ; Cloughesy, T....
Neuro-Oncology. 16 (2014) suppl 5 - p. v153-v153 , 2014

Link: https://doi.org/10.1093/..

15

NI-22 * NON-ENHANCING TUMOR RESPONSE USING QUANTITATIVE T2 ..:

Ellingson, B. ; Pope, W. ; Nghiemphu, P...
Neuro-Oncology. 16 (2014) suppl 5 - p. v142-v143 , 2014

Link: https://doi.org/10.1093/..